Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172324 | 0.89 | HSD17B10 (0.70) | HSD17B10KDM4EPTPN1ALDH1A1MAPT | |
| SCHEMBL18172337 | 0.88 | HSD17B10 (0.68) | HSD17B10KDM4EKMT2APTPN1ALDH1A1 | |
| SCHEMBL18172326 | 0.83 | KDM4E (0.61) | KDM4EKMT2APTPN1ALDH1A1MAPT | |
| SCHEMBL18172323 | 0.80 | KDM4E (0.57) | HSD17B10KDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL18172339 | 0.80 | KDM4E (0.57) | KDM4EKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL184208 | 0.79 | KDM4E (0.61) | KDM4EKMT2AALDH1A1MAPTMEN1 | |
| SCHEMBL4486670 | 0.79 | KDM4E (0.57) | KDM4EKMT2APTPN1ALDH1A1MAPT | |
| SCHEMBL24506216 | 0.75 | HSD17B10 (0.83) | HSD17B10KDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL184501 | 0.74 | KDM4E (0.55) | KDM4EKMT2AMAPTMEN1LMNA | |
| SCHEMBL24506215 | 0.73 | HSD17B10 (0.78) | HSD17B10KDM4EKMT2APTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3286182-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. Hoffmann-La Roche AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| CN-107207449-A | tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2016169902-A1 | TETRAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577332-B2 | Tetrazole derivatives | MC2R, MC3R, GABRR3 | HSD17B10 1226/4885KDM4E 3257/4885KMT2A 2782/4885 |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | MC2R, MC3R, GABRR3 | HSD17B10 1226/4885KDM4E 3257/4885KMT2A 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.